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A B S T R A C T
Great studies of multiple myeloma (MM) strongly suggested that specific chromosomal changes are of prognostic sig-
nificance in patients with MM1. We have performed cytogenetic analysis and recently fluorescent in situ hybridization
(FISH) on 43 cases of MM. Clonal chromosomal changes were present in 24 (56%) cases. Hyperdiploid karyotype was
found in 12 (50%) cases, hypodiploid in 8 (33%) cases, and 4 (17%) cases had a pseudodiploid karyotype. The most com-
mon numerical abnormalities were gains of whole chromosomes 15, 11, 3 and 6. Whole chromosome losses were also fre-
quent involving chromosomes X, 13, 14, and 8. Most cases showed also structural rearrangements 71% (n=17): del(1p),
dup(1q), del(5q), del(13q), del(17p) and t(11;14)(q13;q32) (n=4, 17%). Chromosome –13/13q deletion was found in 42%
(n=10) cases; complete loss of 13 was observed in 67% (n=7) cases, whereas 33% (n=3) had interstitial deletions. In the
majority of the cases there was a mixture of abnormal and normal metaphases.
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Introduction
Multiple myeloma (MM) is a clonal B-cell malignancy
characterized by proliferation of malignant plasma cells
that accumulate within bone marrow and usually secrete
paraprotein. MM is associated with lytic bone lesions or
diffuse osteoporosis and normal Ig production is im-
paired by immuneparesis (<1% cases are non-secretor)2.
The annual incidence of MM is ~30/1,000,000 patients,
usually incurable, within a median survival of 3 years,
and 10% of patients survive more than 10 years3. Al-
though it occurs in 10% of hematological malignancies,
MM represents less than 1% of the reported malignan-
cies with chromosomal abnormalities4.
The low mitotic index of plasma cells in vivo and as
well in vitro causes chromosomal changes in multiple
myeloma and related disorders to be not well-defined. On
the basis of banded chromosomes, abnormal karyotypes
were found in 30–50% of cases; more often in advanced
stages than in newly diagnosed patients. A number of
studies have demonstrated that MM have highly complex
karyotype in the majority of patients5. Cytogenetic re-
sults revealed hyperdiploid clone characterized by a dis-
tinct pattern of chromosome gains, and hypodiploid clone
often accompanied by –13/13q deletion6. Recent advances
in molecular cytogenetic techniques fluorescent in situ
hybridization (FISH) and comparative genomic hybrid-
ization (CGH) have revealed that chromosome aberra-
tions can be found in the majority of MM cases. Survival
studies have shown that hypodiploidy and missing or
partial deletion 13, and abnormalities of 11q and 22q
have been significantly associated with worse prognosis4.
IgH (14q32) translocations may be primary genetic
events but some variantswill likely be progression events
(secondary translocations)7.
In this study we present 43 cases MM analyzed by
classical and molecular cytogenetics, in the time of diag-
nosis. Two of these cases are archived samples.
Patients and Methods
Bone marrow aspirates were collected from 43 pa-
tients at the time of diagnosis. The age of the patients
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ranged from 49 to 83 years, with a median of 63 years.
Among 43 patients, 24 were women and 19 were men.
For conventional cytogentics, bone marrow aspirates were
processed using 24 hr and 48 hr culture with stimulation.
Two samples previously archived in dimethyl sulfoxide
(DMSO) were washed three times in RPMI 1640.
FISH was performed using specific DNA probes
(Kreatech and Vyses) according manufacture instruc-
tions. To detect aneuploidy centromere probes were used
and for detection 13q14 deletions RB1 and for t(11;14)
IGH/CCND1 specific probes on interphases, mainly 200
cells and three metaphases. Results were abnormal when
the percent of cells with any given chromosome abnor-
mality exceeded the normal cut-off value. All FISH pro-
bes were validated using negative or positive controls.
Results
Among 43 successfully analyzed samples clonal chro-
mosomal abnormalities by GTG- banding (Figure 1) and
FISH was detected in 24 (56%) cases. Two samples ar-
chived in DMSO over year were with satisfactory divid-
ing index. MM has also been successfully studied by
interphone FISH that can be done in nondividing cells
(Figure 2). FISH has been applied for the study of triso-
mies/monosomies, deletion 13, 17p13.1 and transloca-
tions involving 14q32 (IgH) locus. Karyotypes were clas-
sified according to the International System for Human
Cytogenetic Nomenclature (2005) (ISCN 2005)8 into
three categories (Table 1). Hyperdiploid with >46 chro-
mosomes in 12 cases (50%), two of them with incomplete
karyotype, hypodyploid <45 in 8 cases (33%), and pseu-
dodiploid with 46 chromosomes with structural and nu-
merical aberrations in 4 cases (17%). Abnormal karyo-
types were usually complex with multiple numerical and
structural changes. In 7 cases there were only numerical
abnormalities without structural abnormalities. In the
majority of the cases with an abnormal karyotype, there
was a mixture of normal and abnormal metaphases, and
only in three were exclusively abnormal cells.
The most common whole chromosome gains were;
+15 (n=5, 21%), +11 (n=5, 21%), +3 (n=4, 17%), +6
(n=4, 17%), +19 (n=4, 17%) and +21 (n=4, 17%), there
were no gains of chromosomes 2, 8, 16, 22 and Y.
Losses of whole chromosomes were; –13 (n=7, 30%),
–X (n=6, 25%), –14 (n=6, 25%), –8 (n=5, 21%), and –16
(n=4, 17%), there were no losses of chromosomes: 3, 10,
11, 15 and 19.
Structural chromosomal abnormalities were detected
in 71% (n=17) cases. Most frequent deletion was deletion
of chromosomes 1p/q, 5q and 13q. Chromosome –13/13q
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Fig. 1. Hyperdiploid karyotype (GTG banded) with numerical and structural changes.
Fig. 2. Interphase FISH analysis for detection of t(11;14)
(q13;q32). Red hybridization signals represent 11q13
(cyclin D-1) and green signals represent the 14q32.3 re-
gion. The presence of a t(11;14) is indicated by the appear-
ance of a yellow fusion signal that results from colocali-
zation of both probes.
deletion was found in 42% (n=10) of cases; complete loss
of 13 was observed in 67% (n=7) of cases, whereas 33%
(n=3) had interstitial deletions. The fifteen transloca-
tions were mostly complex, chromosomes involved in re-
arrangements were 1p/q in 5, 14q in 4 cases (17%) two
t(11;14)(q13;q32), t(2;14)(q?;q32), and der(14)t(14q32;?).
Isochromosomes of long arms chromosomes: 1, 8, 10 and
17 were present in 4 cases (17%). Addition material of
unknown origin affected chromosomes 14q (n=2.8%)
and 17p (n=2.8%).
Discussion
Cytogenetic analysis of MM have been limited by the
low proliferate activity of plasma cells in culture. Despite
that, chromosome analysis provides a wide array of chro-
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TABLE 1
ABNORMAL KARYOTYPES OF 24 CASES WITH MULTIPLE MYELOMA
Hyperdyploidy
Age/sex Karyotype
1. 79M 60~90,XY,+1,+6,+.…inc[5]/46,XY[25]
2. 49M 53,XY,+6,+7,+…. inc[5]/46,XY[20]
3. 68F
46~48,XX,+del(5)(q13),del(5q23q31),+9,+der(11)t(11p;?),+12,der(19)t(19p;?),der(22)t(22q;?)
[cp25]
4. 51F 47,XX,+9,dm[2]/46,XX[12]
5. ?M 47,XY,+19[3]/46,XY[10]
6. ?F 49,XX,+3,del(6q),t(11;14)(q13;q32),+der(14)t(14q;?),+15[8]/46,XX[6]
7. 58F 54,XX,der(2p),+3,+5,+11,+11,der(12p),+15,+15,i(17)(q10),+21[cp18]/46,XX[6]
8. 69F
59~61,X,–X,–X,der(3q)t(1p;3q),–4,del(7)(q22),–8,i(8)(q10),–13,–14,+15,–16,+18,+19,–20,+21,
–22[9] /46,XX [13]
9. 49M 50–52,XY,+3,+6,+7,del(13q),+19,+21[cp3]/46,XY[15]
10. 68M 47,XY,i(1)(q10),t(1p;7pq;10q),i(10)(q10),+mar[6]/46,XY[3]
11.** ?F
72–74<3n>,XX,del(1q),t(2;14)(q?;q32),+del(5q),+del(5q),t(5q;10q)–8,add(8q),–9,+11,–13,–1
4,–14,+3–5 mar[cp5]/46,XX[7] *
12.** 76F
52,–X,–X,del(1q),+3,+4,+7,+11,–13,der(14)t(14q;?),+17,+18,+19,
der(22)t(1p;22q) [cp4]/46,XX[1] *
Hypodiploidy
13. 77F
44~45,XX,t(1;22)(p32;q11),del(3q),der(5)t(5q;?),–7,del(11p),–13,–13,der(14)t(14q;?),–17,der(1
7)t(17p;?),+18,del(20q),+del(20q),+mar2[cp25]/46,XX[12]
14. 77 M 45,X,–Y[3]/46,XY[30]
15. 66F
43–46,XX,+X,+X,–1,–2,–2,–4,+6,–7,–8,+11,+13,+14,+15,–16,–17,–18,–18,+20,+20,–21,–21,
+mar[cp3]/46,XX[25]
16. 75M 45,X,–Y[3]/46,XY[20]
17. 64M 42–43,XY,–4,–5,–6,–7,–22[cp3]/ 46,XY[18]
18. 57F 45,X,–X[20]
19. 73F 44–45,XX,del(1p),t(5;8)(q35;q11q22),t(6q;10q),–12,–13,–14,–14,+2mar[cp8]
20. 65F
41–42,X,–X,t(1;11)(p13;q13),der(2q?),del(4)(q?27),–8,t(9;22)(q12;q13),t(11;14)(q13;q32),–12,–
13,–14,–16,der(17),t(12;17)(q12;p13)[cp7]/46,XX[30]
Near-diploidy
21. 75M 46,XY,inv(3)(q21q26),?der(15q)[cp3]/ 46,XY[18]
22. 64M 46,XX,t(15;16)(q22;p13?3) [5]/46,XX[20]
23. 73F 46,XX,–8,del(13(q14),+21[cp3]/46,XX[23]
24. 65F 46,XX,del(13)(q14),1–2dmin[2]/46,XX[10]
* Bone marrow samples archived in DMSO
mosome aberrations in proliferating plasma cells from
patients with MM9. On the basis of classical cytogenetic
technique (GTG-banding), abnormal karyotypes were
found in 30–50% of cases10. Interphase FISH studies
with centromeric probes have shown aneuploidy in 80%
to 90% of cases, suggesting that clonal chromosomal ab-
normalities are frequent in those disordes11. Several stu-
dies have shown that aneuploidy has a significant impact
on the prognosis of disease and choice of treatment. In
our study of 43 MM in 56% cases with chromosomal ab-
errations according to their chromosome number three
groups were identified. Hyperdiploid group in 50% cases
with chromosome number greater than 46, chromosome
gains were; +15 (21%), +11 (21%), +3 (17%), +6 (17%),
+19 (17%) and +21 (17%). In some studies, the presence
of certain trisomies was associated with an improved
survival13. Second group 33% cases had hypodiploid ka-
ryotype with 41–45 chromosomes, losses of chromosomes
were; –13 (30%), –X (25%), –14 (25%), –8 (21%), and –16
(17%). Hypodiploid MM is associated with a shorter sur-
vival. Hypodiploidy has been found to be associated with
deletion 13 as a prognostic marker13. Third group was
pseudodiplod with structural and numerical chromoso-
mal aberrations in 17% cases. Chromosome –13/13q dele-
tion was found in 42% cases; complete loss of 13 was ob-
served in 67%, whereas 33% had interstitial deletions.
The biological consequences of t(11;14)(q13;q32) remain
unknown, although it has been shown that the MMs pre-
senting this translocation are unexpectedly less proli-
ferative than others1. Rearrangements of 14q32 were
present in 4 cases (n=4, 17%) two t(11;14)(q13;q32),
t(2;14)(q?;q32), and der(14)t(14q32;?).
Taken together, the results from both the metaphase
and interphase cytogenetic studies support the hypothe-
sis that specific chromosomal aberrations are of major
prognostic relevance in MM. With banded chromosomes
and FISH specific chromosomal abnormalities can be de-
tected easily, thus providing a valuable data. Combina-
tions of recently proposed prognostic factors such as
cytogenetics and international scoring system (ISS)
could readily predict prognosis14.
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CITOGENETSKI REZULTATI 24 SLU^AJA MULTIPLOG MIELOMA
S A @ E T A K
Velika ispitivanja multiplog mieloma (MM) nagla{avaju da su odre|ene kromosomske promjene od indikativnog
zna~aja za pacijente s MM. Izvr{ili smo citogeneti~ke analize, a i u novije vrijeme i florescentnu in situ hibridizaciju
(FISH) na 43 slu~aja sa MM. Klonske kromosomske promjene bile su prisutne kod 24 (56%) slu~aja. Hiperdiploidni
kariotip je na|en kod 12 (50%) slu~aja, hipodiploidni kod 8 (33%) slu~aja, i 4 (17%) slu~aja imalo je pseudodiploidni
kariotip. Naj~e{}e broj~ane nepravilnosti bile su suvi{ci kromosoma 15, 11, 3 i 6. Manjak ~itavih kromosoma bili su ~esti
kod kromosoma X, 13, 14, i 8. Ve}ina slu~ajeva tako|er je pokazala strukturalne preuredbe 71% (n=17): del(1p),
dup(1q), del(5q), del(13q), del(17p) and t (11;14)(q13;q32) (n=4,17%). Kromosom – 13/13q delecija na|en je u 42%
(n=10) slu~aja, potpuni gubitak kromosoma 13 uo~en je kod 67% (n=7) slu~aja, dok je 33% (n=3) bilo s intersticijskom
delecijom. U ve}ini slu~ajeva bile su uz abnormalne prisutne i normalne metafaze.
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